These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 31064780

  • 1. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.
    Molina-Crespo Á, Cadete A, Sarrio D, Gámez-Chiachio M, Martinez L, Chao K, Olivera A, Gonella A, Díaz E, Palacios J, Dhal PK, Besev M, Rodríguez-Serrano M, García Bermejo ML, Triviño JC, Cano A, García-Fuentes M, Herzberg O, Torres D, Alonso MJ, Moreno-Bueno G.
    Clin Cancer Res; 2019 Aug 01; 25(15):4846-4858. PubMed ID: 31064780
    [Abstract] [Full Text] [Related]

  • 2. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G.
    Oncotarget; 2016 Aug 30; 7(35):56295-56308. PubMed ID: 27462779
    [Abstract] [Full Text] [Related]

  • 3. Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation.
    Gámez-Chiachio M, Molina-Crespo Á, Ramos-Nebot C, Martinez-Val J, Martinez L, Gassner K, Llobet FJ, Soriano M, Hernandez A, Cordani M, Bernadó-Morales C, Diaz E, Rojo-Sebastian A, Triviño JC, Sanchez L, Rodríguez-Barrueco R, Arribas J, Llobet-Navás D, Sarrió D, Moreno-Bueno G.
    J Exp Clin Cancer Res; 2022 Sep 26; 41(1):285. PubMed ID: 36163066
    [Abstract] [Full Text] [Related]

  • 4. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W, Bi Y, Zhang J, Kong J, Jiang H, Tian M, Li K, Wang B, Chen C, Song F, Pan X, Shi B, Kong X, Gu J, Cai X, Li Z.
    Oncotarget; 2015 Nov 17; 6(36):38840-53. PubMed ID: 26474285
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
    Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS.
    PLoS One; 2009 Dec 15; 4(12):e8314. PubMed ID: 20016813
    [Abstract] [Full Text] [Related]

  • 13. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T, Truesdell P, Craig AW.
    Breast Cancer Res; 2017 Oct 03; 19(1):110. PubMed ID: 28974266
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 03; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
    Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan Z.
    Cancer Lett; 2018 Aug 28; 430():47-56. PubMed ID: 29746929
    [Abstract] [Full Text] [Related]

  • 20. Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R.
    Shi K, Fang Y, Gao S, Yang D, Bi H, Xue J, Lu A, Li Y, Ke L, Lin X, Jin X, Li M.
    J Control Release; 2018 Jun 10; 279():53-68. PubMed ID: 29655990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.